Navigation Links
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer's Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
Date:8/26/2013

OSAKA, Japan and DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its partner, Zinfandel Pharmaceuticals, Inc. ("Zinfandel"), today announced the initiation of TOMMORROW, a global Phase 3 clinical trial investigating a genetic-based biomarker risk assignment algorithm (risk assignment algorithm) to predict risk of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) within a five year period and to evaluate the efficacy of the investigational low dose pioglitazone (designated AD-4833 for this use) in delaying the onset of MCI due to AD in cognitively normal individuals at high risk as determined by the risk assignment algorithm.

The risk assignment algorithm is comprised of apolipoprotein E (APOE) and TOMM40 genotypes and age. Age and APOE genotype have previously been shown to indicate elevated risk of AD. The addition of TOMM40 is hypothesized to further refine the risk determination.

"To date, there have been a number of avenues investigated with the goal of altering the course of Alzheimer's disease but results have been unsuccessful," said Allen Roses, M.D., Chief Executive Officer, Zinfandel. "This is why the TOMMORROW trial is important. The potential to identify an individual's risk for developing MCI due to AD warrants further investigation."

AD is a devastating disease and diagnoses are increasing as the world's population ages. Currently 35.6 million people worldwide are living with some form of dementia. Studies show that individuals with MCI are at an increased risk of developing AD or another dementia with conversion rates of approximately 15 percent per year.

"AD-4833 is a member of a class of drugs known as PPAR (peroxisome proliferator-activated receptor)-gamma agonists which available data show may have a beneficial role in delaying symptoms of MCI due to AD," noted '/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Takeda Launches New Subsidiary in Peru
2. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
5. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
6. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
7. Takeda to Acquire Inviragen, Inc.
8. Takeda Responds to Verdict in Diabetes Drug Case
9. Takeda Launches New Subsidiary in Ecuador
10. Takeda lanza nueva subsidiaria en Ecuador
11. Scripps Research Institute and Takeda Pharmaceuticals Announce Expanded Research Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015 BioLineRx ... clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and ... has commenced an underwritten public offering of American ... its Ordinary Shares. All of the ADSs in ... JMP Securities is acting as ...
(Date:3/5/2015)... Calif., March 5, 2015  IRIDEX Corporation (Nasdaq: ... and year ended January 3, 2015.  , Revenues ... record for the Company and up 11% from $10.6 million ... million, also a record, up 12% from $38.3 million in ... was 50.1%, up from 48.6% in the fourth quarter of ...
(Date:3/5/2015)... -- BioPhotas, Inc., an FDA registered medical device manufacturer selling ... treat skin, muscle and joint conditions, today announced that ... provide BioPhotas, flagship product, the Celluma, to ... Commenting on the alliance, Patrick Johnson ... at the Warrior Hope and Care Center had suffered ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3
... CardioFocus, Inc., developer of the Endoscopic Ablation ... (AF), convened international leaders in electrophysiology to discuss ... catheter ablation for the treatment of paroxysmal AF. ... German Society for Cardiology Annual Meeting in Mannheim, ...
... SAN DIEGO, April 27, 2011 Neurocrine Biosciences, Inc. (Nasdaq: ... and Chief Executive Officer of Neurocrine Biosciences, will be presenting ...   The live presentation takes place on ... 7:40 a.m. Pacific Time.  The presentation will be webcast and ...
Cached Medicine Technology:International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter 2International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter 3
(Date:3/6/2015)... Magellan Rx Management’s 2014 Medical Pharmacy Trend Report ... and statistics on one of the nation’s biggest drivers ... Management will discuss key findings from the report in ... Spend,” a complimentary March 19 webinar, managed and moderated ... makes up more than a quarter of total drug ...
(Date:3/6/2015)... 06, 2015 The Gluten-Free Certification ... Association, is pleased to announce that Dufflet Pastries, ... has expanded their product line of gluten-free treats ... scrumptious and as satisfying as any of their ... and never contains hydrogenated fats or oils, artificial ...
(Date:3/6/2015)... 2015 Dr. Mark Sowell recently returned from ... AZ. Offering programs for advanced education in the field of ... , As a visiting faculty member of this prestigious ... each time he visits Spear Education to participate in a ... “we are training only the top 10% and those willing ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as ... These dates include the following activities:, ... October 6: Conference Day 1, ending with a Fashion ... 2, ending with Local Entertainment and Dinner , ... Materials Meetings , October 9-10: Textiles in India ...
(Date:3/5/2015)... A Bakersfield, Calif. state court jury returned a verdict ... plaintiff Coleen M. Perry a total of $5.7 million for ... mesh sling device, manufactured by Ethicon, Inc., a subsidiary of ... at Wagstaff & Cartmell in Kansas City, Mo., ... Rich Freese and Tim Goss of Freese & Goss ...
Breaking Medicine News(10 mins):Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2
... AND PENN,S WHARTON IN FULD & COMPANY WAR ... Time in Last Five YearsCAMBRIDGE, Mass., April 13 ... predicted in a public war game that most ... healthcare delivery industries--including Microsoft, McKesson, Kaiser-Permanente, and Allscripts--will ...
... Misonix, Inc. (Nasdaq: MSON ), a ... in Europe is used for the ablation of tumors ... into a new, three year, exclusive distribution agreement with ... in Barcarena, Portugal, for the distribution of the SonaStar(TM) ...
... N.J., April 13 Medco Health Solutions, Inc. (NYSE: ... results in a press release before the market opens on ... hold a conference call to review the financial results, outlook ... access the live conference call via telephone: , Dial ...
... William Pursley, has agreed to become Chairman of Rx for ... For 25 years Mr. Pursley has held major executive positions ... and was on the marketing team that launched Human Growth ... huge success. In 1985 Pursley joined Genzyme Corp as VP ...
... DENVER, April 13 Scotland has announced that it ... Nicola Sturgeon announced the pilot program during a visit ... Friday, April 10, where she met with nurses, clients ... is a voluntary prevention program providing nurse home visitation ...
... Line of Customizable Fitness, Nutrition and Wellness Products Specifically ... scope as the leading global specialty retailer of nutritional ... of women,s products called GNC WELLbeING ... one-source line of whole body health products created exclusively ...
Cached Medicine News:Health News:Rivals Will Drive Toward Alliances or Merge in Healthcare I.T. Industry, National Biz School War Game Predicts 2Health News:Rivals Will Drive Toward Alliances or Merge in Healthcare I.T. Industry, National Biz School War Game Predicts 3Health News:Rivals Will Drive Toward Alliances or Merge in Healthcare I.T. Industry, National Biz School War Game Predicts 4Health News:Misonix Announces New Distribution Agreement for Portugal 2Health News:Misonix Announces New Distribution Agreement for Portugal 3Health News:Medco Announces Date for First-Quarter 2009 Financial Results 2Health News:Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc. 2Health News:Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc. 3Health News:Scotland Announces Establishment of Nurse-Family Partnership Program 2Health News:GNC Launches the First-Ever Comprehensive Line of Whole Body Health Products Exclusively for Fit and Active Women 2Health News:GNC Launches the First-Ever Comprehensive Line of Whole Body Health Products Exclusively for Fit and Active Women 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: